Literature DB >> 11333891

In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb.

M T Puglielli1, A J Zajac, R G van der Most, J L Dzuris, A Sette, J D Altman, R Ahmed.   

Abstract

CD8 T cells drive the protective immune response to lymphocytic choriomeningitis virus (LCMV) infection and are thus a determining force in the selection of viral variants. To examine how escape mutations affect the presentation and recognition of overlapping T-cell epitopes, we isolated an LCMV variant that is not recognized by T-cell receptor (TCR)-transgenic H-2Db-restricted LCMV GP33-41-specific cytotoxic T lymphocytes (CTL). The variant virus carried a single-amino-acid substitution (valine to alanine) at position 35 of the viral glycoprotein. This region of the LCMV glycoprotein encodes both the Db-restricted GP33-43 epitope and a second epitope (GP34-42) presented by the Kb molecule. We determined that the V-to-A CTL escape mutant failed to induce a Db GP33-43-specific CTL response and that Db-restricted GP33-43-specific CTL induced by the wild-type LCMV strain were unable to kill target cells infected with the variant LCMV strain. In contrast, the Kb-restricted response was much less affected. We found that the V-to-A substitution severely impaired peptide binding to Db but not to Kb molecules. Strikingly, the V-to-A mutation did not change any of the anchor residues, and the dramatic effect on binding was therefore unexpected. The strong decrease in Db binding explains why the variant virus escapes the Db GP33-43-specific response but still elicits the Kb-restricted response. These findings also illustrate that mutations within regions encoding overlapping T-cell epitopes can differentially affect the presentation and recognition of individual epitopes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333891      PMCID: PMC114915          DOI: 10.1128/JVI.75.11.5099-5107.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Viral escape at the molecular level explained by quantitative T-cell receptor/peptide/MHC interactions and the crystal structure of a peptide/MHC complex.

Authors:  A C Tissot; C Ciatto; P R Mittl; M G Grütter; A Plückthun
Journal:  J Mol Biol       Date:  2000-09-29       Impact factor: 5.469

2.  Single H2Kb, H2Db and double H2KbDb knockout mice: peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses.

Authors:  B Pérarnau; M F Saron; B Reina San Martin; N Bervas; H Ong; M J Soloski; A G Smith; J M Ure; J E Gairin; F A Lemonnier
Journal:  Eur J Immunol       Date:  1999-04       Impact factor: 5.532

3.  Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo.

Authors:  H Pircher; D Moskophidis; U Rohrer; K Bürki; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1990-08-16       Impact factor: 49.962

4.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

5.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen.

Authors:  H Pircher; K Bürki; R Lang; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

6.  Impaired anti-viral T cell responses due to expression of the Ly49A inhibitory receptor.

Authors:  A J Zajac; R E Vance; W Held; D J Sourdive; J D Altman; D H Raulet; R Ahmed
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

7.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Authors:  T M Allen; D H O'Connor; P Jing; J L Dzuris; B R Mothé; T U Vogel; E Dunphy; M E Liebl; C Emerson; N Wilson; K J Kunstman; X Wang; D B Allison; A L Hughes; R C Desrosiers; J D Altman; S M Wolinsky; A Sette; D I Watkins
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

8.  HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population.

Authors:  P O de Campos-Lima; R Gavioli; Q J Zhang; L E Wallace; R Dolcetti; M Rowe; A B Rickinson; M G Masucci
Journal:  Science       Date:  1993-04-02       Impact factor: 47.728

9.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays.

Authors:  A Sette; J Sidney; M F del Guercio; S Southwood; J Ruppert; C Dahlberg; H M Grey; R T Kubo
Journal:  Mol Immunol       Date:  1994-08       Impact factor: 4.407

10.  Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence.

Authors:  R Ahmed; A Salmi; L D Butler; J M Chiller; M B Oldstone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  26 in total

1.  Bi-specific MHC heterodimers for characterization of cross-reactive T cells.

Authors:  Zu T Shen; Michael A Brehm; Keith A Daniels; Alexander B Sigalov; Liisa K Selin; Raymond M Welsh; Lawrence J Stern
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

2.  A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes.

Authors:  Urs Christen; Kurt H Edelmann; Dorian B McGavern; Tom Wolfe; Bryan Coon; Meghann K Teague; Stephen D Miller; Michael B A Oldstone; Matthias G von Herrath
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

3.  T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation.

Authors:  Sarah E Henrickson; Thorsten R Mempel; Irina B Mazo; Bai Liu; Maxim N Artyomov; Huan Zheng; Antonio Peixoto; Michael P Flynn; Balimkiz Senman; Tobias Junt; Hing C Wong; Arup K Chakraborty; Ulrich H von Andrian
Journal:  Nat Immunol       Date:  2008-01-20       Impact factor: 25.606

4.  Local Cellular and Cytokine Cues in the Spleen Regulate In Situ T Cell Receptor Affinity, Function, and Fate of CD8+ T Cells.

Authors:  Young-Jin Seo; Prithiviraj Jothikumar; Mehul S Suthar; Cheng Zhu; Arash Grakoui
Journal:  Immunity       Date:  2016-11-15       Impact factor: 31.745

5.  Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines.

Authors:  Jennifer D Bassett; Stephanie L Swift; Heather VanSeggelen; Joanne A Hammill; A J Robert McGray; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

Review 6.  T cell recognition of weak ligands: roles of signaling, receptor number, and affinity.

Authors:  Lindsay J Edwards; Brian D Evavold
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

7.  Early precursor T cells establish and propagate T cell exhaustion in chronic infection.

Authors:  Daniel T Utzschneider; Sarah S Gabriel; David Chisanga; Renee Gloury; Patrick M Gubser; Ajithkumar Vasanthakumar; Wei Shi; Axel Kallies
Journal:  Nat Immunol       Date:  2020-08-24       Impact factor: 25.606

8.  Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection.

Authors:  Joseph N Blattman; E John Wherry; Sang-Jun Ha; Robbert G van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

9.  Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion.

Authors:  Eunseon Ahn; Ben Youngblood; Junghwa Lee; Judong Lee; Surojit Sarkar; Rafi Ahmed
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Protracted course of lymphocytic choriomeningitis virus WE infection in early life: induction but limited expansion of CD8+ effector T cells and absence of memory CD8+ T cells.

Authors:  Elodie Belnoue; Paola Fontannaz-Bozzotti; Stéphane Grillet; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.